Effects of rapamycin in combination with fludarabine on primary chronic lymphocytic leukemia cells

Leuk Lymphoma. 2019 May;60(5):1299-1303. doi: 10.1080/10428194.2018.1529309. Epub 2018 Nov 8.

Authors

Cecilia M Rodriguez^{1

2}, Claudio Bussi², Daniela S Arroyo^{1

2}, Dario Sastre¹, Viviana Heller¹, Carmen Stanganelli³, Irma Slavutsky⁴, Pablo Iribarren²

Affiliations

¹ a Hospital Nacional de Clínicas, Facultad de Ciencias Médicas , Universidad Nacional de Córdoba , Córdoba , Argentina.
² b Centro de Investigación en Bioquímica Clínica e Inmunología (CIBICI-CONICET) Facultad de Ciencias Químicas , Universidad Nacional de Córdoba , Córdoba , Argentina.
³ c Patología Molecular , Instituto de Investigaciones Hematológicas Academia Nacional de Medicina , Buenos Aires , Argentina.
⁴ d Laboratorio de Genética de Neoplasias Linfoides , Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina , Buenos Aires , Argentina.

PMID: 30407097
DOI: 10.1080/10428194.2018.1529309

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biomarkers
Biomarkers, Tumor
Disease Susceptibility
Female
Flow Cytometry
Gene Expression
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / etiology
Leukemia, Lymphocytic, Chronic, B-Cell / mortality
Male
Mutation
Sirolimus / administration & dosage
Treatment Outcome
Vidarabine / administration & dosage
Vidarabine / analogs & derivatives

Substances

Biomarkers
Biomarkers, Tumor
Vidarabine
fludarabine
Sirolimus